deltatrials
Unknown PHASE1 INTERVENTIONAL 2-arm NCT05502393

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics of JS107 in Patients With Advanced Solid Tumors

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Conditions Advanced Solid Tumors
Interventions JS107 Toripalimab
Updated 4 times since 2022 Last updated: Aug 14, 2022 Started: Jul 26, 2022 Primary completion: Jul 31, 2024 Completion: Dec 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Tumors and is currently ongoing. Shanghai Junshi Bioscience Co., Ltd. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshotRecruiting~Feb 2025 – present · 19 months · monthly snapshotUnknown

Change History

4 versions recorded

  1. Feb 2025 — Present [monthly]

    Unknown PHASE1

    Status: Recruiting → Unknown

  2. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Sep 2022 — Jul 2024 [monthly]

    Recruiting PHASE1

    First recorded

Jul 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Junshi Bioscience Co., Ltd.
Data source: Shanghai Junshi Bioscience Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations